ABCL AbCellera Biologics (ABCL) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001703057
Cluster · 3 insidersC-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
75
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $47.5K priced
What the filings say about ABCL
Insiders, 180 days
+$1.6M net bought
3 buyers
AbCellera Biologics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, AbCellera Biologics Inc. insiders bought a net $1.6M of stock across 39 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Aug 12, 2026.
- -5.1% median (-5.1% mean) 90-day return after 2 previous buys.
- The trade is 3.9% of the 1,373,397 shares held after it.
- 2 other insiders bought within 30 days.
- 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hayden Michael R bought about $570.4K of ABCL on Aug 24, 2026; 2 other insiders bought within 30 days and 75 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on May 14, 2026.
- +1.7% median (+15.7% mean) 90-day return after 9 previous buys.
- The trade is 4.0% of the 251,000 shares held after it.
- 2 other insiders bought within 30 days.
- 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Montalbano John S. bought about $110.3K of ABCL on Aug 18, 2026; 2 other insiders bought within 30 days and 75 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Feb 27, 2026.
- +19.8% median (+25.7% mean) 90-day return after 4 previous buys.
- The trade is 7.7% of the 482,800 shares held after it.
- 2 other insiders bought within 30 days.
- 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Booth Andrew bought about $383.9K of ABCL on Aug 14, 2026; 2 other insiders bought within 30 days and 75 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Sep 22, 2023.
- -5.1% median (-5.1% mean) 90-day return after 2 previous buys.
- The trade is 3.5% of the 1,319,784 shares held after it.
- 2 other insiders bought within 30 days.
- 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hayden Michael R bought about $481.0K of ABCL on Aug 12, 2026; 2 other insiders bought within 30 days and 75 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Nov 26, 2025.
- -2.8% median (+0.8% mean) 90-day return after 8 previous buys.
- The trade is 8.3% of the 241,000 shares held after it.
- No other insider bought within 30 days.
- 75 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Montalbano John S. bought about $95.4K of ABCL on May 14, 2026; 75 funds added in the latest 13F quarter.39 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$1.6M over 180 days
+$1.5M over 90 days
more than 91% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
75 funds bought in last quarter
more than 58% of Pharma & Biotech
Revenue
+160.6% year over year
more than 88% of Pharma & Biotech
Margin
-194.9% net margin
below 65% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
15.6% of the float short (float per yahoo 2026-10-26) · 6.0 days to cover · settled 2026-09-30
more than 73% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ABCL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+120.8%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ABCL: institutional holders (13F)
13F holdings, latest reported quarter
33,012,138 sh
$259.1M
13,588,349 sh
$106.7M
10,437,431 sh
$81.9M
9,568,149 sh
$72.6M
6,141,539 sh
$48.2M
Congress trades in ABCL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ABCL planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ABCL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Counterpoint Quantitative Equity ETF
$7.6M position · as of 2026-06-30
2.1%
iShares Genomics Immunology and Healthcare ETF
$2.9M position · as of 2026-07-31
1.5%
Virtus Biotech Clinical Trials Etf
$338.7K position · as of 2026-07-31
0.7%
Driehaus Micro Cap Growth Fund
$1.9M position · as of 2026-06-30
0.3%
State Street(R) SPDR(R) S&P(R) International Small Cap ETF
$1.3M position · as of 2026-06-30
0.2%
Invesco Nasdaq Biotechnology ETF
$100.3K position · as of 2026-05-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
1 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · (1)
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.3M
$7.3M
$2.7M
-92%
+20%
2024
$8.2M
-$347.5K
$3.2M
-93%
-9%
2023
$714.9K
-$14.6M
$664.3K
-86%
-8%
2022
$8.8M
-$12.5M
$4.7M
-75%
-11%
2021
$9.1M
-$122.9M
$4.1M
-64%
-1%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $1.6M bought by insiders over 180 days, 75 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ABCL financials
Revenue growth
+160.6%
XBRL, annual
Net margin
-194.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$66.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ABCL
| FY Dec 2025 | $75.1M |
| FY Dec 2024 | $28.8M |
| FY Dec 2023 | $38.0M |
| FY Dec 2022 | $485.4M |
| FY Dec 2021 | $375.2M |
| Jun 2026 | $4.0M |
| Mar 2026 | $8.3M |
| Dec 2025 | $44.9M |
| Sep 2025 | $9.0M |
| Jun 2025 | $17.1M |
| Mar 2025 | $4.2M |
| Dec 2024 | $5.0M |
| Sep 2024 | $6.5M |
At each fiscal year end
Single quarter
Net margin, TTM
-248.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ABCL
| FY Dec 2025 | -194.9% |
| FY Dec 2024 | -564.8% |
| FY Dec 2023 | -385.0% |
| FY Dec 2022 | +32.7% |
| FY Dec 2021 | +40.9% |
| Jun 2026 | -1,369% |
| Mar 2026 | -519.1% |
| Dec 2025 | -19.9% |
| Sep 2025 | -637.8% |
| Jun 2025 | -203.3% |
| Mar 2025 | -1,077% |
| Dec 2024 | -677.4% |
| Sep 2024 | -785.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$119.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ABCL
| FY Dec 2025 | -$174.1M |
| FY Dec 2024 | -$187.0M |
| FY Dec 2023 | -$120.8M |
| FY Dec 2022 | $206.7M |
| FY Dec 2021 | $186.1M |
| Jun 2026 | $23.8M |
| Mar 2026 | -$37.4M |
| Dec 2025 | -$44.6M |
| Sep 2025 | -$61.5M |
| Jun 2025 | -$45.8M |
| Mar 2025 | -$22.2M |
| Dec 2024 | -$23.6M |
| Sep 2024 | -$47.4M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
current debt only, 2020-12-31 (66 months older than the period end); equity 2026-06-30
Debt to equity ABCL
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-499.67x
TTM operating cash flow over current debt only, 2020-12-31 (66 months older than the period end)
Cash flow to debt ABCL
| FY Dec 2025 | -691.03x |
| FY Dec 2024 | -571.35x |
| FY Dec 2023 | -230.93x |
| FY Dec 2022 | 1,459.79x |
| FY Dec 2021 | 1,287.28x |
| Jun 2026 | -499.67x |
| Mar 2026 | -806.65x |
| Dec 2025 | -691.03x |
| Sep 2025 | -550.27x |
| Jun 2025 | -425.47x |
| Mar 2025 | -412.64x |
| Dec 2024 | -571.35x |
| Sep 2024 | -632.46x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-17.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ABCL
| FY Dec 2025 | -14.5% |
| FY Dec 2024 | -14.7% |
| FY Dec 2023 | -12.3% |
| FY Dec 2022 | +14.0% |
| FY Dec 2021 | +16.5% |
| Jun 2026 | -17.3% |
| Mar 2026 | -14.7% |
| Dec 2025 | -14.5% |
| Sep 2025 | -16.8% |
| Jun 2025 | -15.6% |
| Mar 2025 | -15.6% |
| Dec 2024 | -14.7% |
| Sep 2024 | -15.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-12.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ABCL
| FY Dec 2025 | -10.8% |
| FY Dec 2024 | -11.4% |
| FY Dec 2023 | -9.7% |
| FY Dec 2022 | +11.1% |
| FY Dec 2021 | +13.2% |
| Jun 2026 | -12.2% |
| Mar 2026 | -10.9% |
| Dec 2025 | -10.8% |
| Sep 2025 | -12.5% |
| Jun 2025 | -11.8% |
| Mar 2025 | -12.0% |
| Dec 2024 | -11.4% |
| Sep 2024 | -12.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ABCL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +20.6% |
| FY Dec 2021 | +36.4% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-17.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ABCL
| FY Dec 2025 | -16.9% |
| FY Dec 2024 | -23.7% |
| FY Dec 2023 | -17.0% |
| FY Dec 2022 | +16.5% |
| FY Dec 2021 | +19.5% |
| Jun 2026 | -17.4% |
| Mar 2026 | -16.8% |
| Dec 2025 | -16.9% |
| Sep 2025 | -20.1% |
| Jun 2025 | -20.8% |
| Mar 2025 | -24.6% |
| Dec 2024 | -23.7% |
| Sep 2024 | -22.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ABCL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 20.26x |
| FY Dec 2021 | 30.43x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$3.6B
market value at close 2026-10-26 on 2026-08-03 shares, plus current debt only, 2020-12-31 (66 months older than the period end), minus cash 2026-06-30
Enterprise value ABCL
| FY Dec 2025 | $895.4M |
| FY Dec 2024 | $709.3M |
| FY Dec 2023 | $1.5B |
| FY Dec 2022 | $2.5B |
| FY Dec 2021 | $3.6B |
| Jun 2026 | $2.3B |
| Mar 2026 | $981.2M |
| Dec 2025 | $895.4M |
| Sep 2025 | $1.4B |
| Jun 2025 | $931.6M |
| Mar 2025 | $505.4M |
| Dec 2024 | $709.3M |
| Sep 2024 | $639.7M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3.2%
TTM free cash flow over market value at close 2026-10-26
FCF yield ABCL
| FY Dec 2025 | -17.0% |
| FY Dec 2024 | -21.6% |
| FY Dec 2023 | -7.3% |
| FY Dec 2022 | +7.1% |
| FY Dec 2021 | +4.6% |
| Jun 2026 | -5.0% |
| Mar 2026 | -17.9% |
| Dec 2025 | -17.0% |
| Sep 2025 | -10.2% |
| Jun 2025 | -13.6% |
| Mar 2025 | -21.6% |
| Dec 2024 | -21.6% |
| Sep 2024 | -25.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ABCL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 3.17x |
| FY Dec 2021 | 4.46x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $75.1M | $28.8M | $38.0M | $485.4M |
| Operating income | -$217.1M | -$314.8M | -$237.2M | $216.5M |
| Net income | -$146.4M | -$162.9M | -$146.4M | $158.5M |
| EPS (diluted) | -0.49 | -0.55 | -0.51 | 0.50 |
| Operating cash flow | -$131.3M | -$108.6M | -$43.9M | $277.4M |
| Cash | $128.5M | $156.3M | $133.3M | $386.5M |
SEC XBRL, fiscal years, as known on 2026-10-27
ABCL Stock Sonar score 6/7 axes
Find similar shapesCompareABCL ranks highest on insider conviction (90th percentile) and growth (88th), and lowest on risk and compliance (36th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ABCL filings, in plain words
Are AbCellera Biologics insiders buying or selling ABCL?
In the 180 days to 2026-10-27, AbCellera Biologics insiders were net buyers, a net $1.6M across purchases and sales reported on Form 4, by 3 buyers.
Read the full summary
In the 180 days to 2026-10-27, AbCellera Biologics insiders were net buyers of ABCL, a net $1.6M across purchases and sales reported on Form 4 by 3 buyers. 3 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
